Obesity is a major cause for the development of debilitating diseases such as type-2 diabetes, cardiovascular disease, hypertension, renal diseases, non-alcoholic steatohepatitis (NASH), all of which reduce life quality as well as lifespan. Despite enormous efforts to develop anti-obesity medications, the drugs that are currently available have had only marginal effects (in the range of 3?10%) on body weight, and most have been withdrawn from the market owing to their side effects. Therefore, there is an urgent need for safe and effective medical treatments for obesity Leptin, an adipose tissue-derived hormone that communicates the status of peripheral energy reserves to the brain has robust influence on appetite suppression and on increasing energy expenditure. These features of leptin initially created great excitement for the treatment of obesity; however the development of leptin resistance in the brains of obese individuals has prevented its use as an effective anti-obesity therapeutic. We and others have previously shown that increased Endoplasmic Reticulum (ER) stress in leptin- responsive neurons in the brain plays a central role in the development of leptin resistance, and consequently of obesity. To translate our molecular biology discoveries into treatment, we used systems biology approaches and unconventional in-silico drug screens powered with mathematical algorithms, to target ER stress. We have discovered Celastrol and Withaferin A as powerful chemical chaperones that alleviate ER stress, restore insulin and leptin sensitivity, and reduce the bodyweight of obese mice to lean levels. The effect of Celastrol on bodyweight (~45-50% reduction) is stronger than that which follows bariatric surgery. We have subsequently focused on the molecular mechanisms of action of Celastrol in increasing leptin sensitivity. These efforts revealed interleukin 1 receptor 1 (IL1R1) as an intermediate mediator of Celastrol's action: we have shown that IL1R1 KO mice are completely resistant to Celastrol's leptin sensitizing and anti- obesity effect. Our proposal is based on these previous observations and has three Specific Aims.
Aim 1 and Aim 2 focus on identification of hypothalamic neuron populations that mediate Celastrol's anti-obesity and anti- diabetic effects. Furthermore, these aims plan to determine the contribution of each identified neuron population to the different aspects of Celastrol's anti-obesity and anti-diabetic effects.
Aim3 proposes to determine the molecular mechanisms of Celastrol action and utilizes state-of-art techniques to identify molecular networks affected by Celastrol. The ultimate goal of this aim is to determine the exact target of Celastrol in mediating leptin sensitization and consequently its anti-obesity and anti-diabetic effects.

Public Health Relevance

Leptin, a hormone secreted from adipocytes, suppresses appetite and creates a strong anorectic response through its action on the brain. However, because a majority of obese individuals develop resistance to leptin, its use as a therapeutic agent alone has not been viable. In this application, we propose to investigate the molecular mechanisms of Celastrol's anti-obesity effect, which is mediated through increasing leptin sensitivity.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Hyde, James F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston Children's Hospital
United States
Zip Code
Lee, Jaemin; Salazar Hernández, Mario Andrés; Auen, Thomas et al. (2018) PGC-1? functions as a co-suppressor of XBP1s to regulate glucose metabolism. Mol Metab 7:119-131
Lee, Jaemin; Liu, Junli; Feng, Xudong et al. (2016) Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat Med 22:1023-32
Liu, Junli; Ibi, Dorina; Taniguchi, Koji et al. (2016) Inflammation Improves Glucose Homeostasis through IKK?-XBP1s Interaction. Cell 167:1052-1066.e18
Herrema, Hilde; Zhou, Yingjiang; Zhang, Dongyan et al. (2016) XBP1s Is an Anti-lipogenic Protein. J Biol Chem 291:17394-404
Liu, Junli; Lee, Jaemin; Salazar Hernandez, Mario Andres et al. (2015) Treatment of obesity with celastrol. Cell 161:999-1011
Herrema, Hilde; Lee, Jaemin; Zhou, Yingjiang et al. (2014) IRS1Ser³?? phosphorylation does not mediate mTORC1-induced insulin resistance. Biochem Biophys Res Commun 443:689-93
Cakir, Isin; Ozcan, Umut (2014) Mom's milk molds neural wiring for metabolism. Cell 156:396-7
Lee, Jaemin; Ozcan, Umut (2014) Unfolded protein response signaling and metabolic diseases. J Biol Chem 289:1203-11
Ozcan, Umut (2013) Mitofusins: mighty regulators of metabolism. Cell 155:17-8